Brazil stands as Latin America's largest medical device market, regulated by ANVISA with recent updates to accommodate new technologies and international harmonization.
Brazil is the largest medical device market in Latin America. The Brazilian regulatory registry for medical devices and in-vitro diagnosis is managed by ANVISA (National Health Surveillance Agency). ANVISA is responsible for regulating the registration of medical devices and in-vitro diagnosis products in the country. The registration process can be complex, but with the help of a specialized Pure Global team you can navigate the regulatory maze more easily. Pure Global has an extensive global expertise, and service network, supported by innovative AI technology in regulatory affairs to Brazil market, and can help you understand the entire registration process for your medical device or in-vitro diagnosis product in Brazil.
The RDC (Resolution of the Collegiate Board) 751/2022 published by ANVISA has just become effective on March 1st of 2023. The main purpose of the change in the Brazilian regulation regarding medical devices was to modernize it, making it possible to address new technologies that were not foreseen in the previous RDC 185/2001, such as software as medical devices (SaMD) and nano-materials. In addition, the RDC implements the MERCOSUL Resolution GMC 25/2021, agreed among Argentina, Paraguay, Uruguay and Brazil, and shows an effort of the Brazilian regulatory agency in harmonizing its concepts and required documents internationally, especially with the International Medical Device Regulators Forum (IMDRF), formed by Australia, Brazil, Canada, China, EU, Japan, Russia, Singapore, South Korea, UK and US. Brazil is part of the Medical Device Single Audit Program (MDSAP) and co-founder of the International Medical Device Regulators Forum (IMDRF).
The regulation applies to all medical devices that fall into its definition provided in the regulation, which is very similar from the one from EU-MDR. Used or reconditioned medical devices, custom-made devices, drugs, cell, tissue, organ or blood from human origin or derivatives, cosmetics, sanitizing or food products for which there is specific regulation apart are out of the scope of the resolution.
In December 2023, the Brazilian National Health Surveillance Agency (ANVISA) updated the RDC (Resolution of the Collegiate Board) 830/2023 covering In Vitro Diagnostic (IVD) Medical Devices, bringing it closer to the one on Medical Devices RDC (Resolution of the Collegiate Board) RDC 751/2022 and abandoning the previous Regulation, Resolução Da Diretoria Colegiada – RDC Nº 36, de 2015 (RDC 36/2015). The new RDC (Resolution of the Collegiate Board) 830/2023 published by ANVISA has an effective date of June 1, 2024.
ANVISA, the regulatory authority responsible for medical device regulatory affairs in Brazil, categorizes medical devices into four main types: medical equipment, materials for health use, orthopedic implants, and in vitro diagnostics (IVD). The risk classification of medical devices is determined by the potential risks associated with their use, ranging from Class I (low risk) to Class IV (high risk).
In medical device regulatory affairs in Brazil, ANVISA issues market authorizations based on the device's risk classification. For products classified as Risk Class I and II, the market authorizations do not have an expiration date. However, they can be canceled upon request, during reassessment, if irregularities cannot be resolved, or in cases of detected fraud. On the other hand, pre-market approvals for products in Risk Class III and IV are valid for 10 years from the date of publication in the Brazilian Official Gazette, with the option for renewal in equal and successive periods.
For IVDs, the registration process follows a similar pattern to that of medical devices. The risk classification, which also ranges from Class I (low risk) to Class IV (high risk), dictates the market authorizations, ensuring consistency across the medical device regulatory framework in Brazil.
When it comes to registering your medical device or in-vitro diagnosis product in Brazil, partnering with Pure Global can be a positive step. Here are some reasons why:
The regulations RDC 751/2022 and RDC 830/2023 have brought about some changes to the registration process for medical devices and in-vitro diagnosis products in Brazil. Pure Global have professionals with years of experience with wealth of experience in regulatory affairs in Brazil and can help you understand the entire registration process for your medical device or in-vitro diagnosis product in Brazil. With our expertise, local knowledge, and efficiency, we can help you navigate the regulatory landscape more easily and ensure that your medical device or in-vitro diagnosis product is registered smoothly.
Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.
.png)
As 2024 comes to a close, Pure Global proudly reflects on a transformative year marked by substantial growth, cutting-edge innovation, and impactful collaborations.
IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.
(3).png)
On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.
Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.